title: Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
abstract: BACKGROUND
  We retrospectively evaluated the efficacy of weekly paclitaxel therapy as second-line treatment for patients with advanced gastric cancer that was refractory to S-1.
  
  
  METHODS
  In total, 33 patients received intravenous paclitaxel (80 mg m(-2)) on days 1, 8 and 15 as part of a 4-week cycle.
  
  
  RESULTS
  Eight patients showed a partial response, 11 showed stable disease and 14 showed disease progression. In total, 171 courses (mean=5.2; range=3-16) were administered. Thirteen cases subsequently underwent third-line treatment. The median survival time and time to progression from the time of second-line treatment was 8.0 months and 4.2 months, respectively. The most common haematological toxicities were leukopenia and neutropenia. Non-haematological toxicities were generally mild to moderate and controllable.
  
  
  CONCLUSIONS
  This study showed favourable therapeutic outcomes for advanced gastric cancer patients. However, it will be necessary to confirm the advantages of paclitaxel treatment for S-1-refractory advanced gastric cancer in a larger population.
authors: Department of Surgery, Gastroenterological Center,Graduate School of Medicine, Yokohama City University, Japan.
authors: Goro
authors: G
authors: Matsuda
authors: Chikara
authors: C
authors: Kunisaki
authors: Hirochika
authors: H
authors: Makino
authors: Michiko
authors: M
authors: Fukahori
authors: Jun
authors: J
authors: Kimura
authors: Tsutomu
authors: T
authors: Sato
authors: Takashi
authors: T
authors: Oshima
authors: Yasuhiko
authors: Y
authors: Nagano
authors: Shoichi
authors: S
authors: Fuii
authors: Ryo
authors: R
authors: Takagawa
authors: Takashi
authors: T
authors: Kosaka
authors: Hedetaka A
authors: HA
authors: Ono
authors: Hirotoshi
authors: H
authors: Akiyama
authors: Yasushi
authors: Y
authors: Ichikawa
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel